Cargando…
Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260166/ https://www.ncbi.nlm.nih.gov/pubmed/35811704 http://dx.doi.org/10.3389/fcvm.2022.916705 |
| _version_ | 1784741960970403840 |
|---|---|
| author | Rawal, Shalin Sharma, Kamal Shah, Aditya Bavishi, Shriya Christian, Cleris Bhatt, Parjanya Konat, Ashwati |
| author_facet | Rawal, Shalin Sharma, Kamal Shah, Aditya Bavishi, Shriya Christian, Cleris Bhatt, Parjanya Konat, Ashwati |
| author_sort | Rawal, Shalin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9260166 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92601662022-07-08 Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy Rawal, Shalin Sharma, Kamal Shah, Aditya Bavishi, Shriya Christian, Cleris Bhatt, Parjanya Konat, Ashwati Front Cardiovasc Med Cardiovascular Medicine Frontiers Media S.A. 2022-06-23 /pmc/articles/PMC9260166/ /pubmed/35811704 http://dx.doi.org/10.3389/fcvm.2022.916705 Text en Copyright © 2022 Rawal, Sharma, Shah, Bavishi, Christian, Bhatt and Konat. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Cardiovascular Medicine Rawal, Shalin Sharma, Kamal Shah, Aditya Bavishi, Shriya Christian, Cleris Bhatt, Parjanya Konat, Ashwati Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy |
| title | Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy |
| title_full | Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy |
| title_fullStr | Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy |
| title_full_unstemmed | Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy |
| title_short | Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy |
| title_sort | commentary: cost-effectiveness analysis of rivaroxaban plus aspirin compared with aspirin alone in patients with coronary and peripheral artery diseases in italy |
| topic | Cardiovascular Medicine |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260166/ https://www.ncbi.nlm.nih.gov/pubmed/35811704 http://dx.doi.org/10.3389/fcvm.2022.916705 |
| work_keys_str_mv | AT rawalshalin commentarycosteffectivenessanalysisofrivaroxabanplusaspirincomparedwithaspirinaloneinpatientswithcoronaryandperipheralarterydiseasesinitaly AT sharmakamal commentarycosteffectivenessanalysisofrivaroxabanplusaspirincomparedwithaspirinaloneinpatientswithcoronaryandperipheralarterydiseasesinitaly AT shahaditya commentarycosteffectivenessanalysisofrivaroxabanplusaspirincomparedwithaspirinaloneinpatientswithcoronaryandperipheralarterydiseasesinitaly AT bavishishriya commentarycosteffectivenessanalysisofrivaroxabanplusaspirincomparedwithaspirinaloneinpatientswithcoronaryandperipheralarterydiseasesinitaly AT christiancleris commentarycosteffectivenessanalysisofrivaroxabanplusaspirincomparedwithaspirinaloneinpatientswithcoronaryandperipheralarterydiseasesinitaly AT bhattparjanya commentarycosteffectivenessanalysisofrivaroxabanplusaspirincomparedwithaspirinaloneinpatientswithcoronaryandperipheralarterydiseasesinitaly AT konatashwati commentarycosteffectivenessanalysisofrivaroxabanplusaspirincomparedwithaspirinaloneinpatientswithcoronaryandperipheralarterydiseasesinitaly |